Abbott's XIENCE PRIME stent wins FDA approval

11/2/2011 | Reuters

The FDA has granted Abbott Laboratories approval for its XIENCE PRIME everolimus-eluting stent for use in treating patients with coronary artery disease. The device has an improved design that allows more flexibility and accuracy in stent delivery and placement.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA